⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153961 | 1.00 | — | — | |
| SCHEMBL7782903 | 1.00 | — | — | |
| SCHEMBL1676891 | 1.00 | — | — | |
| SCHEMBL1676791 | 1.00 | — | — | |
| SCHEMBL2153675 | 1.00 | — | — | |
| SCHEMBL2155118 | 1.00 | — | — | |
| SCHEMBL2155057 | 1.00 | — | — | |
| SCHEMBL2154219 | 1.00 | — | — | |
| SCHEMBL2153937 | 1.00 | — | — | |
| SCHEMBL2154801 | 1.00 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257152-A2 | APELIN POLYPEPTIDES | Amgen Inc. (US) | 2023-10-11 | — | — | EP | claimed |
| EP-3509573-B1 | PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF PEPTIDE | ANYA BIOPHARM INC (TW) | 2023-05-24 | — | — | EP | claimed |
| EP-3674314-B1 | APELIN POLYPEPTIDES | AMGEN INC (US) | 2023-05-03 | — | — | EP | claimed |
| US-10941182-B2 | Apelin polypeptides | AMGEN INC. (US) | 2021-03-09 | — | — | US | claimed |
| EP-3674314-A2 | APELIN POLYPEPTIDES | Amgen, Inc (US) | 2020-07-01 | — | — | EP | claimed |
| US-20190112348-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2019-04-18 | — | — | US | claimed |
| US-10259856-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2019-04-16 | — | — | US | claimed |
| US-9688737-B2 | Protease stabilized acylated insulin analogues | NOVO NORDISK A/S (DK) | 2017-06-27 | — | — | US | claimed |
| CN-106794252-A | Pharmaceutical formulations for oral delivery of peptide or protein drugs | 塞浦路迈德有限责任公司 | 2017-05-31 | — | — | CN | claimed |
| US-20170107255-A1 | APELIN POLYPEPTIDES | AMGEN INC. (US) | 2017-04-20 | — | — | US | claimed |
| EP-3155002-A2 | APELIN POLYPEPTIDES | Amgen Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| US-9512195-B2 | Insulin derivatives containing additional disulfide bonds | NOVO NORDISK A/S (DK) | 2016-12-06 | — | — | US | claimed |
| CN-102985440-B | Insulin derivatives comprising additional disulfide bonds | 诺沃-诺迪斯克有限公司 | 2016-10-26 | — | — | CN | claimed |
| EP-2254906-B1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2016-10-05 | — | — | EP | claimed |
| EP-2910571-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | claimed |
| US-20150210747-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | claimed |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | claimed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | claimed |
| EP-2254906-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | claimed |
| WO-2009115469-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | WO | claimed |